Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (590)	1/28/2000 1:46:00 AM
From: N/E PATSFAN	Respond to of 52153

[immt] >> Immtech's data indicates that rmCRP therapy, like angiogenesis inhibitor therapy, targets blood vessels. Unlike angiogenesis inhibitors, which block the growth of new vessels, rmCRP works to strengthen existing normal tissues. Immtech's biological therapeutics program is uniquely focused on strengthening the human body's most basic immune system defenses, helping the body reestablish effective tissue barriers to the entry and spread of disease throughout the body. Strengthened tissues also allow the body's intrinsic immune system to more effectively and efficiently combat disease << There's an interesting and "greener" approach to combat disease - no wonder you've got an interest in CRP! It is a little pricey right now with a pull back in the markets likely but I'll start to acquire some asap but with the small float (2.6M), that may be difficult... thanks as usual, NEPF

To: scaram(o)uche who wrote (590)	1/28/2000 10:40:00 AM
From: Torben Noerup Nielsen	Read Replies (2) \| Respond to of 52153

Given all of the recent economic data, I think a 50 point interest rate hike is more and more likely. The currency markets seem to be leaning in that direction too. But I'm sort of curious. Is this really bad for biotech? Most of the better ones do not seem to be terribly affected by interest rates. And they're not selling into a market that is heavily influenced by how much money Joe Consumer has in his pocket. In a way, I'd think it's a good thing since there're still a lot of undervalued biotechs around with significant appreciation potential. A hike in interest rates is more likely to curb the current wild consumer borrowing which will impact high tech sales - people won't buy quite as many PCs and other toys on credit - but that should simply accelerate the already started sector rotation. I'm not an economist so could anyone enlighten me as to what I'm missing here? Yes, it'll mean turbulence for a bit. But it looks like the market is already busy pricing in a 50 point hike and given that, I don't see how the Federal Reserve can do anything else now. And once they actually announce it, the market should quiet down since it won't be an uknown any longer. And it'll be mostly priced in. Thanks, Torben